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Introduction
Many 1,2,3,4-tetrahydroisoquinolines exhibit variousb ioactivities, such as antitumor, antibacterial, antiviral, anticoagulant, anti-inflammatory,a nti-Alzheimer, and anticonvulsant activities. [1] Among them, members of the saframycin, renieramycin, and ecteinascidin families have captured intense attentiond ue to their interesting biological activities and intriguing structures ( Figure 1 ). Particularly,n ovel marine-derived ecteinascidin 743 [2] (2,T rabectedin, Yondelis) has superior antitumor activity and was approved by the European Commission in 2007 [3] and the US Food and Drug Administration (FDA) in 2015 [4] for the treatment of soft-tissue sarcomas. Al arge number of renieramycinm arine natural products [5] have been discovered in sponges of genera Reniera, [6] Xestospongia, [7] Haliclona, [8] Cribrochalina, [9] and Neopetrosia [10] in miniscule amounts. In our continuing chemical studies on renieramycins, [11] we found that the transformation of an unstable aminal group in an aturalp roduct,s uch as renieramycin E (1a), into an aminonitrile group by pretreatment with KCN prior to extraction and isolation furnished many kinds of stable renieramycin derivatives, such as renieramycinM (1b). [12] We also elucidated the chemical structure of renieramycin T( 1c), which wasi solated from the blue sponge Xestospongia sp. in Thailand [11c] and the Philippines. [11b] RenieramycinT (1c)p ossesses ah ighly substituted phenol in the terminal Aring and a condensed 1,3-dioxole ring, which are exactly the same as those in ecteinascidins.A st he chemical structure of 1c is the first example of ah ybrid pentacyclic core, we are very interested in the biosynthetic pathway and the biological activity of 1c and its derivatives. To date, two total syntheses of (À)-1c by us and Chen's group have been reported. [13] However,w e focusedo na na lternative route for supplying al arge amount of 1c to promote research of structure-activity relationships. Herein, we report aformal total synthesis of 1c,which includes the Pictet-Spenglerr eaction of ap rimary amine with an oxomalonic acid ester followed by decarboxylation and stereocontrolled protonation at C1 of the enol intermediate from the less-hinderedf ace. [14] 
Results and Discussion
We embarked on an alternative total synthesis of 1c on the basis of our previoussynthetic studies on saframycin antitumor Af ormal total synthesis of the antitumorm arine naturalp roduct (rac)-renieramycin T, which possessesacharacteristic ecteinascidin-type Aring in the renieramycin-saframycin core skeleton, was elaborated. The key steps in the synthesis of (rac)-renieramycin Tare am odified Pictet-Spengler cyclization of dialkylatedo xomalonate derivatives and decarboxylation via a monocarboxylic acid derivativef ollowed by stereocontrolled protonation of the enol intermediate. Ak ey intermediate in our previous synthesis of renieramycinT was used, and the formal synthesis was accomplished in 21 steps from ak nown piperazine-2,5-dione derivative. [a] S. Kimura,Prof. Dr.N .S aito Graduate School of Pharmaceutical Sciences Meiji PharmaceuticalUniversity 2-522-1 Noshio, Kiyose, Tokyo, 204-8588 (Japan) E-mail:naoki@my-pharm.ac.jp antibiotics(Scheme 1). [15] Condensationofhighly functionalized benzaldehyde 4 [16] with known piperazine-2,5-dione derivative 5
[15b] afforded Z isomer 6 in 79 %y ield. Chemoselectiver eduction of the carbonyl group activated by an isopropyloxycarbonyl group in 6,f ollowed by treatment with trifluoroacetic acid (TFA) gave cyclized product 7 (78 %, two steps). Removal of the isopropoxycarbonyl group in 7 with TFAa nd H 2 SO 4 gave as econdary amine that was treated with aN aBH 3 CNaqueous formaldehyde system to provide tertiary amine 8 in 68 %o verall yield. Hydrogenation (2.8 MPa) of the exo olefin in 8 on 20 %P d(OH) 2 in EtOH at 80 8Ca long with hydrogen attack from the less-hindered a face gave 9 as as ingle isomer in 77 %y ield. At that point, we thought it would be important to distinguish the two phenolicO Hg roupsi nb oth terminal rings, because regioselective oxidation was required to prepare p-quinonei nt he Ering phenol at al ater stage. Thus, the phenolic OH group of the Ering of 9 was protectedw ith an allyl group, and the tosyl group in the Aring wasr emoved with KOH/H 2 Ot oi ncrease its reactivity for the Pictet-Spengler cyclization to give 10 in 80 %over two steps.
With precursor 10 in hand, we focused on the construction of ap entacyclic core by using the Pictet-Spengler cyclization (Scheme 2). Partial reduction of the lactam carbonyl group in 10,f ollowedb yt he introduction of ac yanide group gave aminonitrile 11.W eh ad hoped that the aminonitrile would be more reactivet han lactam 10 in the Pictet-Spengler cyclization. However,i tw as revealed that the Pictet-Spengler cyclization of 11 with even commonly used simple aldehydes, [15c] for example, the reaction of 11 with benzoyloxyacetaldehyde, did not proceed at all. [17] Furthermore, substrate decomposition was observed if harsher reaction conditions were used. It was clarified that the aminonitrile moietyof11 was relatively unstable under acidic or high-temperature conditions. Therefore, we abandoned this route at this stage.
This problem was solved by applying our protocol to the total synthesis of saframycin A( 3,S cheme 3). [18] Primary amine I did not have ar elatively unstablea minonitrile group,a nd so steric repulsion would be reduced. Thus,i tw ould be easy to construct desired pentacyclic core IV by using at hree-step sequencet hrough compound II,w hich includes the Pictet-Spengler cyclization with oxomalonic acid ester to install ad iester unit, decarboxylation, and stereoselective protonation from the convex face of these "V"-shaped bis-1,2,3,4-tetrahydroisoquinoline natural products.
Activation of the lactam carbonyl group in 10 with di-tertbutyl dicarbonate (Boc 2 O) gave 13 in 72 %y ield according to a protocoli ndependently outlined by Fukuyama and Stoltz [19] (Scheme 4). Reductivec leavage of the lactam ring in 13 with NaBH 4 in EtOH, followed by treatment with TFAi nCH 2 Cl 2 gave primary amine 14 (73 %, two steps). Pictet-Spengler cyclization of 14 with allyl ethyl oxomalonate hydrate [20] furnished diester 15 as an inseparable diastereomericm ixture (1:1) in 80 %y ield. Then, the phenolic OH group in 15 was protected by ab enzyl (Bn) group (83 %), and Swern oxidation of 16 followed by treatment with KCN afforded pentacyclic core 17 (56 %, two steps). Removal of the allyl group in 17 with Pd(PPh 3 ) 4 and dimedone, followed by decarboxylation exclusivelyg ave ester 18 as as ingle diastereomer in 72 %y ield. [21, 22] The stereochemistry of 18 was determined by nuclear Overhauser enhancement (NOE) experiments, which indicated that 18 had a syn relationship between the C1 and C3 diaxial protons.
Finally,r eductiono fe ster 18 (71 %), followed by oxidative demethylation of 19 into quinone ring afforded 20 (51 %) (Scheme5). This is the key intermediate in our total synthesis; [13a] its 1 HNMR, 13 CNMR, andI Rs pectroscopy data;M Sd ata; and TLC behavior were identicalt ot hose of an authentic sample upon comparison Thus, we accomplished af ormal synthesis of (rac)-renieramycin T(1c).
Conclusions
We accomplished af ormal synthesis of (rac)-renieramycin T (1c). Whereas the aromatic ring having a1 ,3-dioxole ring suppressed reactivityd uring the Pictet-Spengler cyclization,r eductive cleavage of the lactam ring in 13 afforded primary amine 14.T hen, treatmento f14 with allyl ethyl oxomalonate in the Pictet-Spengler reaction, followed by decarboxylation and stereoselective protonation of the resulting enol intermediate fromt he less-hindered face produced the desired bis-1,2,3,4-tetrahydroisoquinoline intermediate.
Ways of utilizing this strategy for the synthesis of ecteinascidins along with fennebricin B [23] are under investigation in our laboratory.
Experimental Section GeneralM ethods
All reactions involving air-and moisture-sensitive reagents were performed in oven-dried glassware and by using standard syringeseptum cap techniques. All reactions were monitored by thin-layer chromatography (silica gel GF 254 )e xamined under UV light (l = 254 nm). 4 Si as the internal standard. Low-and highresolution mass (HRMS) mass spectra were recorded with aJ MS-700 instrument with ad irect inlet system operating at 70 eV.
As olution of tBuOK in tBuOH (1 m,3 0mL, 30 mmol) was added dropwise to as tirred solution of aldehyde 4 (8.36 g, 25 mmol) and acetate 5 (11.66 g, 25 mmol) in CH 2 Cl 2 (100 mL) at 0 8Co ver 1h, and the mixture was stirred at 0 8Cf or 1h.T he mixture was diluted with saturated aqueous NH 4 Cl solution (200 mL) and extracted with CH 2 Cl 2 (3 250 mL). The combined extract was washed with brine (200 mL), dried, and concentrated in vacuo to give ar esidue (18.26 g) , which was subjected to flash column chromatography on SiO 2 (500 g) with hexane/EtOAc (3:2) to afford 6 (14.62 g, 79 %) as ac olorless amorphous powder; R f = 0.35 (hexane/EtOAc 1:1);
, 149.5 (C-2' or 5'), 149.3 (C-2' or 5'), 148.1 (C-4' or 7"a), 148.0 (C-4' or 7"a), 145.6 (C-3"a), 145.4 (C 6 H 4 CH 3 ), 141.8 (C-6"), 132.3 (C 6 H 4 CH 3 ), 130.1 (C 6 H 4 CH 3 ), 128.7 (C 6 H 4 CH 3 ), 125.9 (C-3'), 124.7 (C-5), 122.3 (C-1'), 119.7 (C-5"), 117.1 (C-7"), 113.9 (C-5a), 112.9 (C-6'), 104.6 (C-4"), 102.3 (C-2"), 100.0 (CH 2 OCH 3 ), 72.0 (CH(CH 3 ) 2 ), 60.1 (4'-OCH 3 ), 59.9 (C-2), 57.6 (CH 2 OCH 3 ), 55.8 (5'-OCH 3 ), 33.8 (C-2a), 21.8 (CH(CH 3 ) 2 ), 21.8 (CH(CH 3 ) 2 ), 21.5 (C 6 H 4 CH 3 ), 10.9 (7"-CH 3 ), 10.4 ppm (3'-CH 3 ); FTIR (KBr): ñ = 1773, 1694, 1479, 1420, 1375, 1281, 1233, 1196, 1173, 1103, 1080, 1061, 1022, 972, 806 (Z)-Isopropyl (1R*,5S*)-7-hydroxy-9,10-dimethoxy-8-methyl-2-{ [7-methyl-6-(tosyloxy) 2,3,4,5,6-hexahydro-1,5-iminobenzo[d] azocine-11-carboxylate (7) Li(tBuO) 3 AlH (6.36 g, 25 mmol) was added to as tirred solution of 6 (3.70 g, 5mmol) in THF (170 mL) at 0 8Co ver 40 min, and the mixture was stirred at 25 8Cf or 6h.T he mixture was diluted by adding as aturated aqueous Rochelle salt solution (100 mL) and was then extracted with CHCl 3 (3 300 mL). The combined extract was washed with brine (300 mL), dried, and concentrated in vacuo to give aresidue, which was used in the next step without further purification. TFA( 22.5 mL) was added to as tirred solution of the above product (3.71 g) in CH 2 Cl 2 (45 mL), and the mixture was stirred at 25 8Cf or 3h.T he mixture was concentrated in vacuo, and the residue was diluted with H 2 O( 200 mL). Then, the mixture was brought to pH 9w ith concd. NH 4 OH (25 mL) and was extracted with CH 2 Cl 2 (3 300 mL). The combined extract was washed with brine (300 mL), dried, and concentrated in vacuo to give aresidue (3.75 g), which was subjected to column chromatography on SiO 2 (100 g) with CHCl 3 /EtOAc (4:1) [D 6 ]DMSO, 100 8C): d = 167.6 (C-1), 152.5 (CO 2 ), 149.1 (C-7 or 9), 148.3 (C-7 or 9), 145.4 (C-7'a), 145.1 (C 6 H 4 CH 3 ), 144.6 (C-3'a), 142.5 (C-10a), 139.6 (C-6'), 133.9 (C-2 or 5' or 7'), 132.4 (C 6 H 4 CH 3 ), 129.4 (C 6 H 4 CH 3 ), 127.5 (C 6 H 4 CH 3 ), 124.0 (C-8 or 6a or 10a), 121.7 (C-2 or 5' or 7'), 118.5 (C-8 or 6a or 10a), 114.8 (C-8 or 6a or 10a), 114.0 (C-2 or 5' or 7'), 106.0 (C-4'), 101.3 (C-2'), 101.2 (C-2a), 68.8 (CH(CH 3 ) 2 ), 59.5 (10-OCH 3 ), 59.2 (9-OCH 3 ), 51.6 (C-5), 48.8 (C-1), 26.0 (C-6), 21.2 (CH(CH 3 ) 2 ), 21.2 (CH(CH 3 ) 2 ), 20.6 (C 6 H 4 CH 3 ), 9.8 (7'-CH 3 ), ; FTIR (KBr): ñ = 3379, 1684, 1476, 1458, 1420, 1373, 1352, 1298, 1275, 1248, 1217, 1192, 1180, 1167, 1109, 1078, 1024, 1001, 816, 808 (Z)-{(1R*,5S*) 2, 3, 4, 5, 4, 5, (8) Anisole (1.1 mL, 10 mmol) and concd. H 2 SO 4 (2.4 mL) were successively added to as tirred solution of 7 (1.36 g, 2mmol) in TFA (47.6 mL) at 0 8C, and the mixture was stirred at 25 8Cf or 7.5 h. After the mixture was diluted with H 2 O( 800 mL) at 0 8C, it was made alkaline with concd. NH 4 OH (75 mL) and was then extracted with CHCl 3 (2 700 mL) and, finally,C HCl 3 /MeOH (9:1, 2 700 mL). The combined extract was dried and concentrated in vacuo to give aresidue, which was used in the next step without further purification. 1460, 1418, 1371, 1352, 1215, 1192, 1179, 1165, 1115, 1078 {(1R*,2S*,5S*)- 2, 3, 4, 5, 
As uspension of 8 (608.7 mg, 1mmol) (C-4) , 149.8 (C-9), 147.9 (C-7), 146.1 (C-7'a), 145.7 (C-3'a), 145.3 (C 6 H 4 CH 3 ), 144.8 (C-10), 141.2 (C-6'), 133.7 (C 6 H 4 CH 3 ), 129.9 (C 6 H 4 CH 3 ), 127.9 (C 6 H 4 CH 3 ), 124.6 (C-5'), 121.8 (C-6a or 10a), 117.5 (C-8), 115.4 (C-7'), 114.6 (C-6a or 10a), 107.5 (C-4'), 101.8 (C-2'), 60.5 (9-OCH 3 ), 60.2 (10-OCH 3 ), 58.1 (C-5), 55.9 (C-2), 54.4 (C-1) (10) As olution of 9 (1.36 g, 2.23 mmol) in acetone (110 mL) was stirred in the presence of K 2 CO 3 (1.55 g, 11.14 mmol) at 0 8C, allyl bromide (385 mL, 4.45 mmol) was added over 10 min, and the mixture was heated at reflux for 5.5 h. The mixture was filtered, and the combined filtrate was concentrated in vacuo to give ar esidue, which was used in the next step without further purification. An analytical sample was obtained as ac olorless amorphous powder by column chromatography with EtOAc to EtOAc/MeOH 1674, 1476, 1450, 1414, 1358, 1339, 1192, 1180, 1113, 1076 3370, 2936, 1655, 1476, 1456, 1412, 1339, 1252, 1238, 1184, 1111,1 092, 1076 (14), 234 (39), 233 (24), 219 (13), 218 (47) (1R*,2S*,4R*,5S*)
As uspension of Cp 2 ZrHCl (31.9 mg, 0.12 mmol) in THF (0.5 mL) was added to as tirred solution of 10 (19.9 mg, 0.04 mmol) in THF (1 mL) at À20 8C, and the mixture was warmed to 0 8Co ver 1h.A solution of KCN (20.8 mg, 0.32 mmol) in H 2 O(640 mL) was added to the above solution, and the mixture was stirred at 25 8Cf or 4h.
The mixture was diluted with saturated aqueous NaHCO 3 solution (10 mL) and extracted with CHCl 3 (3 15 mL). The combined extract was washed with brine (10 mL), dried, and concentrated in vacuo to give ar esidue (21.5 mg), which was subjected to column chromatography on SiO 2 (6 g) with CHCl 3 C-7) , 150.0 (C-9), 148.2 (C-6'), 147.6 (C-10), 145.4 (C-7'a), 140.2 (C-3'a), 133.7 (OCH 2 CH=CH 2 ), 124.5 (C-8), 123.0 (C-6a), 122.0 (C-10a), 119.0 (CN), 117.3 (OCH 2 CH=CH 2 ), 115.8 (C-5'), 108.8 (C-7'), 107.2 (C-4'), 100.7 (C-2'), 72.9 (OCH 2 CH= CH 2 ), 60.4 (10-OCH 3 ), 60.2 (9-OCH 3 ), 57.7 (C-2), 56.6 (C-1), 53.9 (C-5), 53.5 (C-4), 42.0 (NCH 3 ), 34.2 (C-2a), 21.3 (C-6), 9.7 (8-CH 3 ), 9.1 ppm (7'-CH 3 ); FTIR (KBr): ñ = 3447, 2936, 2361, 1458, 1412, 1250, 1111, 1092, 1074, 1055, 1042, 1020 9,10-dimethoxy-8,11-dimethyl-4-oxo-1,2,5,6-tetrahydro-1,5-iminobenzo[d] azocine-3(4H)-carboxylate (13) Am ixture of 10 (568.5 mg, 1.14 mmol) and DMAP (279.4 mg, 2.29 mmol, 2equiv) in MeCN (11.5 mL) was cooled at 0 8C; then, Boc 2 O( 5.3 mL, 22.90 mmol, 20 equiv.) was added to the mixture, which was heated at reflux for 17.5 h. As the starting material still remained, as indicated by TLC monitoring, DMAP (279.4 mg, 2.29 mmol, 2equiv.) was added to the mixture at 25 8C, and the reaction mixture was heated under reflux for an additional 40 h. The mixture was diluted with H 2 O( 30 mL) and extracted with CHCl 3 (3 50 mL). The combined extract was washed with brine (50 mL), dried, and concentrated in vacuo to give ar esidue, which was subjected to column chromatography on SiO 2 (15 g) with hexane/ EtOAc (11:9) to afford 13 (570.9 mg, 72 %) as ab rown amorphous powder; R f = 0.30 (hexane/EtOAc 11:9); 4.26 (ddt, J = 12.4, 5.4, 1.5 Hz, 1H ,C H 2 CH= CH 2 ), 3.77 (dd, J = 7.7, 1.5 Hz, 1H, 3.72 (s, 3H, ), 3.61 (s, 3H,1 0-OCH 3 ), 3.07 (dd, J = 18.5, 7.7 Hz, 1H, 2.96 (dd, J = 18.5, 1.5 Hz, 1H, 1757, 1732, 1697, 1477, 1456, 1412, 1395, 1369, 1341, 1275, 1256, 1152, 1099, 1063 6-(2'S*)-(1"R,3"S)- 2", 3", 
NaBH 4 (892.4 g, 23. 59 mmol) was added to as tirred solution of 13 (821.8 mg, 1.179 mmol) in EtOH (12 mL) at 0 8C, and the mixture was stirred at 25 8Cf or 3h.T he mixture was diluted with saturated aqueous NH 4 Cl (10 mL) and H 2 O( 40 mL) at 0 8Ca nd extracted with CHCl 3 (3 50 mL). The combined extract was washed with brine (30 mL), dried, and concentrated in vacuo to give ar esidue, which was used in the next step without further purification. An analytical sample of the protected compound (857.3 mg) was obtained as ac olorless amorphous powder by column chromatography with hexane/EtOAc ( 4.27 (dd, J = 12.5, 5.6 Hz, 1H ,C H 2 CH=CH 2 ), 4.12 (dd, J = 12.5, 5.6 Hz, 1H ,C H 2 CH=CH 2 ), 1H, 3.86 (s, 3H, , 3.83 (s, 3H, 3.77 (d, J = 9.5 Hz, 1H, 3.48 (dd, J = 11.3, 3.3 Hz, 1H, 3.13 (br d, J = 13.1 Hz, 1H, 2.88 (dd, J = 15.5, 4.8 Hz, 1H, 2.75 (dd, J = 15.5, 12.6 Hz, 1H, .0 (C-5'), 149.0 (C-7'), 146.5 (C-8'), 145.0 (C-7"a), 144.6 (C-3"a), 142.4 (C-6"), 133.9 (CH 2 CH=CH 2 ), 126.7 (C-4'ao r8 'a), 125.9 (C-4'ao r 8'a), 124.0 (C-6' or 5"), 123.8 (C-6' or 5"), 117.4 (CH 2 CH=CH 2 ), 112.9 (C-7"), 106.8 (C-4"), 101.2 (C-2"), 83.5 (C(CH 3 ) 3 ), 78.3 (C(CH 3 ) 3 ), 74.1 (CH 2 CH=CH 2 ), 64.4 (C-2), 63.7 (C-1'), 63.1 (C-3'), 60.5 (8'-OCH 3 ), 60.1 (7'-OCH 3 ), 55.6 (C-1), 46.6 (NCH 3 ), 32.6 (C-3'a), 28.1 (C (CH 3 ) 3 ), 27.6 (C (CH 3 ) 3 ) , 24.4 (C-4'), 9.50 (6'-CH 3 ), 9.45 ppm (7"-CH 3 ); FTIR (KBr): ñ = 3422, 2978, 2930, 1751, 1715, 1516, 1477, 1458, 1369, 1281, 1258, 1153, 1101, 1063 -3a) , 139.3 (C-7a), 133.5 (CH 2 CH=CH 2 ), 126.7 (C-8"a), 124.8 (C-4"a or 6"), 124.6 (C-4"a or 6"), 117.7 (CH 2 CH=CH 2 ), 117.6 (C-6), 109.3 (C-4), 107.0 (C-7), 100.5 (C-2), 74.5 (CH 2 CH=CH 2 ), 65.0 (C-1"), 63.9 (C-3"a), 63.0 (C-3"), 60.7 (8"-OCH 3 ), 60.1 (7"-OCH 3 ), 59.1 (C-2'), 46.6 (NCH 3 ), 38.2 (C-1'), 24.3 (C-4"), 9.7 (6"-CH 3 ), 9.3 ppm (4-CH 3 ); FTIR (KBr): ñ = 3441, 3370, 2938, 2866, 1470, 1414, 1248, 1115, 1094, 1057, 934 (6aS*,7R*,13S*,14R*,16R*)-Ethyl 5-(benzyloxy)- 14-cyano-11-hydroxy-8,9-dimethoxy-4,10,17-trimethyl-6a,7,12,13,14,16-hexahydro-6H-7,13-iminobenzo[4,5] azocino- [1,2-b] - [1, 3] dioxolo [4,5-h] isoquinoline-16-carboxylate (18) 14!15:As olution of 1-allyl 3-ethyl 2,2-dihydroxymalonate [20] (238.2 mg, 1.167 mmol) in TFA( 6mL) was added to as tirred solution of 14 (116.8 mg, 0.233 mmol) in AcOH (1.5 mL), and the mixture was stirred at 25 8Cf or 6h.T he mixture was diluted with H 2 O (60 mL) at 0 8C, made alkaline with concentrated NH 4 OH (11mL), and extracted with CHCl 3 (3 80 mL). The combined extract was washed with brine (40 mL), dried, and concentrated in vacuo to give ar esidue (358.9 mg), which was subjected to column chromatography on SiO 2 (10 g) with hexane/EtOAc (2:3) to afforda ni nseparable 1:1d iastereomer mixture of 15 (124.9 mg, 80 %) as a yellow amorphous powder. (25 mL, 0.3 mmol) was added to as tirred solution of DMSO (43 mL, 0.6 mmol) in CH 2 Cl 2 (1 mL) at À78 8C, and the mixture was stirred at À78 8Cf or 15 min. As olution of 16 (45.5 mg, 60 mmol) in CH 2 Cl 2 (1 mL) was added to the above solution at À78 8Co ver 10 min, and the mixture was stirred at À78 8Cf or 4h. Et 3 N( 167 mL, 1.2 mmol) was then added to the mixture at À78 8C over 5min, and stirring was continued at À78 8Cf or 30 min. After the mixture was warmed to 25 8Co ver ap eriod of 3h and stirred for 2h,i tw as diluted with saturated aqueous NaHCO 3 solution (5 mL) at 0 8Ca nd extracted with CHCl 3 (3 10 mL). The combined extract was washed with brine (10 mL), dried, and concentrated in vacuo to give ar esidue that was used in the next step without purification. As olution of KCN (31.9 mg, 0.48 mmol) in H 2 O( 960 mL) was added to as tirred solution of the crude product (63.4 mg) in THF (1 mL) in the presence of AcOH (381 mL, 6.6 mmol) at 0 8C, and the mixture was stirred at 25 8Cf or 2h.T he mixture was diluted with saturated aqueous NaHCO 3 (5 mL) at 0 8Ca nd extracted with CHCl 3 (3 10 mL). The combined extract was washed with brine (10 mL), dried, and concentrated in vacuo to give ar esidue (41.5 mg), which was subjected to column chromatography on SiO 2 (6 g) with hexane/EtOAc (3:1) to afford an inseparable 1:1d iastereomer mixture of 17 (25.8 mg, 56 %, two steps) as ac olorless amorphous powder.
17!18:
As olution of Pd(PPh 3 ) 4 (16.4 mg, 13.8 mmol) in THF (1.0 mL) was added to as tirred solution of 17 (35.2 mg, 46 mmol) and dimedone (32.6 mg, 0.23 mmol) in THF (2.0 mL) under an argon atmosphere, and the mixture was stirred at 25 8Cf or 1h. After the mixture was concentrated in vacuo, the resulting residue was dissolved in CHCl 3 (2.5 mL) and heated at reflux for 2h.T he mixture was concentrated in vacuo to give ar esidue, which was subjected to column chromatography on SiO 2 (6 g) with CHCl 3 / EtOAc (4:1) to afford 18 (21.2 mg, 72 %, two steps) as ap ale-yellow amorphous powder; R f = 0.20 (CHCl 3 /EtOAc 4:1);
